About IMAGIN

Imagin Diagnostic Centres, Inc. (Imagin) has a unique investment strategy for the development of diagnostic molecular imaging commencing globally in Canada. Imagin through strategic acquisitions in the PET scan centres, Positron Emitting Radiopharmaceuticals (PER’s) and PET equipment businesses is well-positioned to make a significant positive impact to worldwide medicine and critical disease. Critical disease is defined as cancer, heart disease and neurological disorders such as Alzheimer’s and Parkinson’s disease. PET scan technology is essential in the diagnosis, staging and treatment planning for critical disease.